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Influenza-related illnesses have caused an estimated over million cases of severe illness, and it has about 
hundred thousands of deaths worldwide annually. Traditionally these vaccines are produced in embryonated 
chicken eggs. However, in the case of a pandemic outbreak, this egg-based production system may not be 
quickly enough to meet the surging demand. The efficacy associated with egg-based vaccines are low in 
recently years. The raising concerns with egg-derived vaccines is resulting in the spurred exploration of 
alternatives. MDCK cells are becoming as an alternative host to embryonated eggs for influenza virus 
propagation. Although MDCK cells were considered to be a suitable host for the virus production, their inability 
to grow in suspension still limits the process of scale-up and their production capability. 
 
Table 1. Virus titers of pandemic and seasonal influenza vaccine strains grown in sMDCK 
cells. 
Virus Source HA unit/50 µL 
received adapted  
A/Vietnam/1194/2004 (H5N1)  NIBSC 
Egg-derived 
512 989  
A/Anhui/1/2013 (H7N9) 256 996  
A/Singapore/GP2050/2015 (H3N2) VIDRL 
Cell-derived 
 
n.a n.a.  
B/Brisbane/63/2014 (Victoria) 1337.2 1708.8  
B/Brisbane/9/2014 (Yamagata) 838.2 1552.9  
 
 
In this study, NHRI, Taiwan and Irvine Scientific, USA has developed a suspension MDCK cell line and 
proprietary medium (BalanCD simple MDCK). The cell concentration of the suspension MDCK (sMDCK) cells 
up to 2 × 106 cells/ml after 96 hrs was obtained, and the doubling time of 30-35 hrs was found very similar to the 
adhesion MDCK (aMDCK)cells cultivated on microcarriers (5g/L). In addition, no fresh medium replacement was 
necessary in the sMDCK cell culture during the cell growth stage. The H7N9 candidate vaccine virus (NIBRG-
268 which was derived from A/Anhui/1/2013) was used and infected both sMDCK and aMDCK cells with a low 
multiplicity of infection. The harvest of viruses was collected on day three post infection. The HA titers in sMDCK 
and aMDCK cells were reached to 996 and 574 HA units/50ul, respectively. The results show that the HA titers 
from both pandemic and seasonal vaccine strains cultured in sMDCK cells are high (see table 1). A similar 
finding was found in the small-scale bioreactor. The animal study also showed higher immunogenic response 
over the antigen produced from the aMDCK cell culture. Based on the overall recovery yield (30%) and the 
consumable cost from medium usage, the production cost is similar to the egg process. 
 
In summary, a new adapted sMDCK cell line was developed.  This sMDCK cultured using chemical-define (CD) 
medium can remain the similar growth rates as aMDCK cells but showed higher viral titers in both pandemic and 
seasonal influenza strains. Thus, this new combined technology of sMDCK with specifically-optimized CD 
medium could provide a low-cost vaccine production to the bottlenecks for establishing a large-scale cell culture 
using adherent MDCK cells. 
 
 
 
